<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816045</url>
  </required_header>
  <id_info>
    <org_study_id>REG-032-2020</org_study_id>
    <nct_id>NCT04816045</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Electrochemotherapy for Colorectal Cancer - a Randomized Controlled Trial</brief_title>
  <official_title>Neoadjuvant Electrochemotherapy for Colorectal Cancer - a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial investigating efficacy of electrochemotherapy for early&#xD;
      colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 randomized controlled trial. The study is blinded. The aim of this study is&#xD;
      to establish the safety and efficacy of treating patients with early colorectal cancer with&#xD;
      electrochemotherapy, compared with electroporation alone, as a down staging and&#xD;
      immune-response enhancing treatment prior to intended curative surgery. The study involves&#xD;
      recruitment of patients with histologically verified rectal and sigmoid colon cancer with no&#xD;
      indication for neoadjuvant chemoradiotherapy (experimental or standard care based) prior to&#xD;
      intended curative surgery. In total the study will involve 24 patients, of these, 12 patients&#xD;
      are treated with electrochemotherapy (bleomycin) and 12 patients with electroporation alone&#xD;
      (placebo)&#xD;
&#xD;
      In relation to the intervention, clinical examination, blood samples, biopsies and&#xD;
      questionnaires will be collected to evaluate safety, tumor respons and immunologic response&#xD;
      to the treatment.&#xD;
&#xD;
      Patients will be followed for one month after the elective surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients and investigators are blinded. The allocation list is located at the pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor stage</measure>
    <time_frame>6 months</time_frame>
    <description>Preoperative tumor stage will be compared with pathological assessment of the surgical specimen and comared between the two study arms using TNM stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gene expressional changes in the tumor microenvironment</measure>
    <time_frame>6 months</time_frame>
    <description>Biopises are collected before the intervention and compared with the surgical specimen using NanoString technology. The PanCancer IO 360 gene panel will be used, a predefined panel of 770 genes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of fusobacterium</measure>
    <time_frame>6 months</time_frame>
    <description>To characterize the spatial distribution and organization of bacteria in situ, some of the samples will be assessed microscopically. Confocal laser scanning microscopy will be performed on formalin-fixed, paraffin-embedded tissue of both diseased and normal tissue. This will allow us to investigate treatment affects the bacterial composition of fusobacterium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-1/PD-L1</measure>
    <time_frame>6 months</time_frame>
    <description>Immunohistochemical staining for PD-1/PD-L1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3</measure>
    <time_frame>6 months</time_frame>
    <description>Immunohistochemical staining for CD3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8</measure>
    <time_frame>6 months</time_frame>
    <description>Immunohistochemical staining for CD8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD28</measure>
    <time_frame>6 months</time_frame>
    <description>Immunohistochemical staining for CD28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAR2</measure>
    <time_frame>6 months</time_frame>
    <description>Immunohistochemical staining for VAR2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electrochemotherapy with bleomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electroporation with saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrochemotheraoy</intervention_name>
    <description>Electrochemotherapy (ECT) is endoscopic electroporation in combination with bleomycin</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroporation with saline (placebo)</intervention_name>
    <description>Electroporation in the control group is performed endoscopically with saline</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be mentally capable of understanding the information given.&#xD;
&#xD;
          -  Patients must give written informed consent.&#xD;
&#xD;
          -  Endoscopically suspected or histologically verified malignant tumor of the rectum or&#xD;
             sigmoid colon.&#xD;
&#xD;
          -  Tumor described as passable at index endoscopy.&#xD;
&#xD;
          -  Men or women aged at least 18 years.&#xD;
&#xD;
          -  Case reviewed by MDT (surgery, radiology, oncology). Case considered curable with&#xD;
             standard surgical resection.&#xD;
&#xD;
          -  ASA class I-II (Classification of the American Society of Anesthesiology)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indication for neoadjuvant chemoradiation or chemotherapy prior to surgery&#xD;
&#xD;
          -  Uncorrectable coagulation disorder.&#xD;
&#xD;
          -  Patients with ICD or pacemaker units.&#xD;
&#xD;
          -  Ongoing immunosuppressive treatment.&#xD;
&#xD;
          -  Patients with concomitant use of phenytoin.&#xD;
&#xD;
          -  Myocardial insufficiency, defined as NYHA class &gt;2&#xD;
&#xD;
          -  Concurrent treatment with an investigational medicinal product.&#xD;
&#xD;
          -  Patients with any other clinical condition or prior therapy that, in the opinion of&#xD;
             the investigator, would make the patient unsuitable for the study or unable to comply&#xD;
             with the study recruitments.&#xD;
&#xD;
          -  Advanced tumor stages, clinical UICC stage IV.&#xD;
&#xD;
          -  Acute surgical resection.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Medical history of severe pulmonary disease.&#xD;
&#xD;
          -  Previous cumulative dose of bleomycin exceeding 250mg/m2.&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
&#xD;
          -  Renal impairment, defined as eGFR &lt;40 ml/min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismail GÃ¶genur, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zealand University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Malene Broholm, MD</last_name>
    <phone>+45 56531500</phone>
    <email>malea@regionsjaelland.dk</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

